Эффективность внутрисуставной терапии препаратами гиалуроновой кислоты у больных остеоартритом
https://doi.org/10.14412/1996-7012-2019-2-96-104
Аннотация
Остеоартрит (ОА) – самое распространенное заболевание опорно-двигательного аппарата, характеризующееся постоянной болью, нарушением функции сустава и ранней потерей трудоспособности. В настоящее время встречаемость ОА выросла и, по данным НИИР им. В.А. Насоновой, составляет около 13%, что в 5 раз превышает показатели официальной статистики. Основные цели лечения ОА – уменьшение боли, улучшение функционального состояния сустава, предотвращение развития деформации сустава, улучшение качества жизни пациентов, а также минимизация побочных эффектов фармакотерапии. Препараты гиалуроновой кислоты (ГНК), предназначенные для внутрисуставного введения, долгое время используются как «протез» синовиальной жидкости, однако в недавно опубликованных работах представлены новые данные о механизмах их действия и роли в лечении больных ОА. В многочисленных метаанализах показано, что терапия ГНК по переносимости существенно не отличается от плацебо, обеспечивая при этом значимое уменьшение боли и улучшение функции сустава.
Обзор посвящен некоторым вопросам применения препаратов ГНК для внутрисуставного введения у пациентов с ОА, механизмам действия ГНК, проблемам выбора препарата в зависимости от источника получения, молекулярной массы, методики введения и эффективности терапии по сравнению с другими препаратами.
Об авторах
Е. А. Стребкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Л. И. Алексеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 240 с.
2. Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe andinternationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.
3. Altman RD. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015 Oct 26;16:321. doi: 10.1186/s12891-015-0775-z.
4. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr; 64(4):465-74.
5. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3): 363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.
6. Julovi SM, Yasuda T, Shimizu M, et al. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004 Feb;50(2): 516-25. doi: 10.1002/art.20004.
7. Koga H. Effects of hyaluronic acid on arthritic articular cartilage. Connect Tissue Res. 2012;53(1):48–93. doi: 10.3109/03008207.2011.637147.
8. Peng H, Zhou JL, Liu SQ, et al. Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro. Inflamm Res. 2010; 59(7):519–530. doi: 10.1007/s00011- 010-0156-x.
9. Mongkhon JM, Thach M, Shi Q, et al. Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and mediators of inflammation and catabolism in human osteoarthritic chondrocytes. Inflamm Res. 2014;63(8):691–701. doi: 10.1007/s00011- 014-0742-4.
10. Williams J. The effects of hyaluronic acid on fibronectin fragment mediated cartilage chondrolysis in skeletally mature rabbits. Osteoarthritis Cartilage. 2003 Jan;11(1):44-9. doi: 10.1053/joca.2002.0864.
11. Kobayashi K, Matsuzaka S, Yoshida Y, et al. The effects of intraarticularly injected sodium hyaluronate on levels of intact aggrecan and nitric oxide in the joint fluid of patients with knee osteoarthritis. Osteoarthritis Cartilage. 2004 Jul;12(7):536-42. doi: 10.1016/j.joca.2004.03.005.
12. Sasaki A, Sasaki K, Konttinen YT, et al. Hyaluronate inhibits the interleukin-1betainduced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. Tohoku J Exp Med. 2004; 204(2):99–107. doi: 10.1620/tjem.204.99.
13. Campo GM, Avenoso A, Nastasi G, et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta. 2011 Sep;1812(9):1170-81. doi: 10.1016/j.bbadis.2011.06.006. Epub 2011 Jun 21.
14. Obara T, Mabuchi K, Iso T, Yamaguchi T. Increased friction of animal joints by experimental degeneration and recovery by addition of hyaluronic acid. Clin Biomech (Bristol, Avon). 1997 Jun;12(4):246-252. doi: 10.1016/S0268- 0033(97)00004-1.
15. Prasadam I, Crawford R, Xiao Y. Aggravation of ADAMTS and matrix metalloproteinase production and role of ERK1/2 pathway in the interaction of osteoarthritic subchondral bone osteoblasts and articular cartilage chondrocytes – possible pathogenic role in osteoarthritis. J Rheumatol. 2012; 39(3):621–634. doi: 10.3899/jrheum.110777.
16. Hiraoka N, Takahashi Y, Arai K, et al. Hyaluronan and intermittent hydrostatic pressure synergistically suppressed MMP-13 and IL-6 expressions in osteoblasts from OA subchondral bone. Osteoarthritis Cartilarge. 2009;17(1):S97. doi: 10.1016/S1063-4584 (09)60186-2.
17. Gotoh S, Onaya J, Abe M, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52(11): 817–822. doi: 10.1136/ard.52.11.817.
18. Pena Ede L, Sala S, Rovira JC, et al. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain. 2002;99(3): 501–508. doi: 10.1016/S0304-3959 (02)00260-9.
19. Tashiro T. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. Scientific World Journal. 2012;2012:167928. doi: 10.1100/2012/167928. Epub 2012 Nov 20.
20. Lindqvist U, Tolmachev V, Kairemo K, et al. Elimination of stabilisedhyaluronan from the knee joint in healthy men. Clin Pharmacokinet. 2002;41(8):603-13.
21. Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther. 2015 Mar 10;17:51. doi: 10.1186/s13075-015-0557-x.
22. Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis--meta-analysis. Osteoarthritis Cartilarge. 2011 Jun;19(6):611-9. doi: 10.1016/j.joca.2010.09.014.
23. Altman RD, Rosen JE, Bloch DA, Hatoum HT. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilarge. 2011 Oct;19(10):1169-75. doi: 10.1016/j.joca.2011.07.001.
24. Leighton R, Akermark C, Therrien R, et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilarge. 2014 Jan;22(1): 17-25. doi: 10.1016/j.joca.2013.10.009.
25. Аникин СГ, Кашеварова НГ, Короткова ТА и др. Оценка эффективности, переносимости и безопасности внутрисуставного введения гиалуроновой кислоты у больных с остеоартритом коленных суставов. Современная ревматология. 2017; 11(3):58-63. doi: 10.14412/1996-7012-2017-3-58-63
26. Алексеева ЛИ, Шарапова ЕП, Зайцева ЕМ и др. Результаты многоцентрового годичного исследования препарата дьюралан. Эффективная фармакотерапия. 2011;(37):50-7.
27. Алексеева ЛИ, Шарапова ЕП, Зайцева ЕМ и др. Применение препарата гиалганфидия при остеоартрозе коленных суставов. Эффективная фармакотерапия. 2011;(39):14-21.
28. Trojian TH, Concoff AL, Joy SM, et al. Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis: Importance for Individual Patient Outcomes. Clin J Sport Med. 2016 Jan;26(1):1-11. doi: 10.1097/JSM.0000000000000274.
29. Brandt KD. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res. 2001 Apr;(385):130-43. doi: 10.1097/00003086-200104000-00021
30. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002 Nov;41(11): 1240-8.
31. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Apr;43(5):593-9. doi: 10.1016/j.semarthrit.2013.10.002.
32. Ishijima M, Nakamura T, Shimizu K, et al. Intra-articular hyaluronic acid injection versus oral non-steroidal anti-inflammatory drug for the treatment of knee osteoarthritis: a multi-center, randomized, open-label, noninferiority trial.; Research Group of Cartilarge Metabolism. Arthritis Res Ther. 2014 Jan 21;16(1):R18. doi: 10.1186/ar4446.
33. Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015 Jan 6;162(1):46-54. doi: 10.7326/M14-1231.
34. Skwara A, Ponelis R, Tibesku CO, et al. Gait patterns after intraarticular treatment of patients with osteoarthritis of the knee – hyaluronan versus triamcinolone: a prospective, randomized, doubleblind, monocentric study. Eur J Med Res. 2009;14(4):157–164.
35. Ran J, Yang X, Ren Z, et al. Comparison of intra-articular hyaluronic acid and methylprednisolone for pain management in knee osteoarthritis: A meta-analysis of randomized controlled trials. Int J Surg. 2018 May;53: 103-110. doi: 10.1016/j.ijsu.2018.02.065.
36. Liu SH, Dube CE, Eaton CB, et al. Longterm Effectiveness of Intraarticular Injections on Patient-reported Symptoms in Knee Osteoarthritis. J Rheumatol. 2018 Aug; 45(9):1316-1324. doi: 10.3899/jrheum.171385.
37. Juni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticularhylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum. 2007 Nov;56(11):3610-9.
38. Altman RD, Bedi A, Karlsson J, et al. Product Differences in Intra-articular Hyaluronic Acids for Osteoarthritis of the Knee. Am J Sports Med. 2016 Aug;44(8): 2158-65. doi: 10.1177/0363546515609599.
39. Navarro-Sarabia F, Coronel P, Collantes E, et al. A 40-month multicentre,randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. Ann Rheum Dis. 2011 Nov;70(11):1957-62. doi: 10.1136/ard.2011.152017. Epub 2011 Aug 17.
40. Benazzo F, Perticarini L, Padolino A, et al. A multi-centre, open label, long-term followup study to evaluate the benefits of a new viscoelastic hydrogel (Hymovis®) in the treatment of knee osteoarthritis. Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):959-68.
41. Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol. 2003 May-Jun; 21(3):307-11.
42. Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg. 2005 Jan;18(1):7-15. 43. Abbott T, Altman RD, Dimef R, et al. Do hyaluronic acid injections delay total knee replacement surgery? Arthritis Rheum. 2013; 65:S910–S911
43. Atamaz F, Kirazli Y, Akkoc Y. A comparison of two different intra-articular hyaluronan drugs and physical therapy in the management of knee osteoarthritis. Rheumatol Int. 2006 Aug;26(10):873-8. Epub 2006 Jan 14.
44. Pal S, Thuppal S, Reddy KJ, Avasthi S, et al. Long-Term (1-Year) Safety and Efficacy of a Single 6-mL Injection of Hylan G-F 20 in Indian Patients with Symptomatic Knee Osteoarthritis. Open Rheumatol J. 2014 Oct 2;8:54-68. doi: 10.2174/1874312901408010054.
45. Petrella RJ, Wakeford C. Pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a high-molecular-weight hyaluronan, versus other treatment options: data from a large real-world longitudinal cohort in Canada. Drug Des Devel Ther. 2015 Oct 15; 9:5633-40. doi: 10.2147/DDDT.S88473.
46. Strand V, Lim S, Takamura J. Evidence for safety of retreatment with a single intraarticular injection of Gel-200 for treatment of osteoarthritis of the knee from the doubleblind pivotal and open-label retreatment clinical trials. BMC Musculoskelet Disord. 2016 Jun 1;17:240. doi: 10.1186/s12891-016-1101-0.
47. Abate M, Vanni D, Pantalone A, Salini V. Hyaluronic acid in knee osteoarthritis: preliminary results using a four months administration schedule. Int J Rheum Dis. 2017 Feb; 20(2):199-202. doi: 10.1111/1756-185X.12572.
48. Pham T, Le Henanff A, Ravaud P, et al. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004 Dec;63(12):1611-7.
49. Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long-term study. Eur J Rheumatol Inflamm. 1995;15:57–62.
50. Bali JP, Cousse H, Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum. 2001;31(1):58–68. doi: 10.1053/sarh.2000.24874.
51. Maheu E, ZaÏm M, Appelboom T, et al. Evaluation of intra articular injections of hyaluronic acid and chondroitine sulfate for knee arthritis treatment: a multicentric pilot study with 3 months follow-up. National rheumatolgy meeting; 2010 (SocieteFraneaise de Rheumatologie).
52. Таскина ЕА, Кашеварова НГ, Шарапова ЕП и др. Оценка эффективности и безопасности гиалурома СS у пациентов с остеоартритом коленных суставов (предварительные данные). Научно-практическая ревматология. 2018;56(приложение 2):77.
53. Miller LE, Block JE. US-approved intraarticular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and metaanalysis of randomized, saline-controlled trials. Clin Med Insights Arthritis Musculoskelet Disord. 2013 Sep 1;6:57-63. doi: 10.4137/CMAMD.S12743. eCollection 2013.
54. Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am. 2002 Jul;84-A(7):1142-7.
55. Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and metaanalysis. Arthritis Rheum. 2007 Dec 15; 57(8):1410-8.
56. Qvistgaard E, Christensen R, TorpPedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis Cartilage. 2006 Feb; 14(2):163-70. Epub 2005 Nov 14.
57. Migliore A, Massafra U, Bizzi E, et al. Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip. Arthritis Res Ther. 2009;11(6): R183. doi: 10.1186/ar2875. Epub 2009 Dec 9.
58. Figen Ayhan F, Ustü n N. The evaluation of efficacy and tolerability of Hylan G-F 20 in bilateral thumb base osteoarthritis: 6 months follow-up. Clin Rheumatol. 2009 May;28(5): 535-41. doi: 10.1007/s10067-008-1080-0.
59. Bahadir C, Onal B, Dayan VY, Gü rer N. Comparison of therapeutic effects of sodium hyaluronate and corticosteroid injections on trapeziometacarpal joint osteoarthritis. Clin Rheumatol. 2009 May;28(5):529-33. doi: 10.1007/s10067-008-1079-6.
60. Heyworth BE, Lee JH, Kim PD, et al. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008 Jan;33(1):40-8. doi: 10.1016/j.jhsa.2007.10.009.
61. Kroon F, Carmona L, Schoones J, Kloppenburg M. Efficacy and safety of nonpharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. RMD Open. 2018 Oct 11;4(2):e000734. doi: 10.1136/rmdopen-2018-000734. eCollection 2018.
Рецензия
Для цитирования:
Стребкова ЕА, Алексеева ЛИ. Эффективность внутрисуставной терапии препаратами гиалуроновой кислоты у больных остеоартритом. Современная ревматология. 2019;13(2):96-104. https://doi.org/10.14412/1996-7012-2019-2-96-104
For citation:
Strebkova EA, Alekseeva LI. Efficiency of intra-articular hyaluronic acid therapy in patients with osteoarthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(2):96-104. (In Russ.) https://doi.org/10.14412/1996-7012-2019-2-96-104
Просмотров:
1132
Послать статью по эл. почте 